48 related articles for article (PubMed ID: 26589790)
1. A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.
Shin DY; Choi YH; Lee HR; Na II; Yuh YJ; Kim BS; Chung IJ; Bae WK; Shim HJ; Song EK; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2016 Jan; 77(1):163-8. PubMed ID: 26589790
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Kang SH; Min SH; Kim JW; Lee E; Park SW; Lee S; Oh HJ; Park YS; Lee YJ; Kim JW; Ahn SH; Suh YS; Lee KW; Lee HS; Kim HH
Ann Surg Oncol; 2022 Aug; 29(8):5084-5091. PubMed ID: 35322307
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract][Full Text] [Related]
4. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
Chung V; McDonough S; Philip PA; Cardin D; Wang-Gillam A; Hui L; Tejani MA; Seery TE; Dy IA; Al Baghdadi T; Hendifar AE; Doyle LA; Lowy AM; Guthrie KA; Blanke CD; Hochster HS
JAMA Oncol; 2017 Apr; 3(4):516-522. PubMed ID: 27978579
[TBL] [Abstract][Full Text] [Related]
5. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Hecht JR; Papadopoulos KP; Falchook GS; Patel MR; Infante JR; Aljumaily R; Wong DJ; Autio KA; Wainberg ZA; Bauer TM; Javle M; Pant S; Bendell J; Hung A; Ratti N; VanVlasselaer P; Verma R; Leveque J; Rao S; Oft M; Naing A
Invest New Drugs; 2021 Feb; 39(1):182-192. PubMed ID: 32910338
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
George TJ; Ali A; Wang Y; Lee JH; Ivey AM; DeRemer D; Daily KC; Allegra CJ; Hughes SJ; Fan ZH; Cameron ME; Judge AR; Trevino JG
Oncologist; 2021 Oct; 26(10):825-e1674. PubMed ID: 34101295
[TBL] [Abstract][Full Text] [Related]
7. Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
Quesada S; Samalin E; Thezenas S; Khellaf L; Mourregot A; Portales F; Mazard T; Ychou M; Adenis A
Anticancer Res; 2022 Jan; 42(1):185-193. PubMed ID: 34969724
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei.
Hiraide S; Komine K; Sato Y; Ouchi K; Imai H; Saijo K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
Int J Clin Oncol; 2020 Apr; 25(4):774-781. PubMed ID: 31823151
[TBL] [Abstract][Full Text] [Related]
9. Tumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma.
Lingamaneni P; Desai P; Vennikandam MM; Moturi K; Baranwal A; Gupta S
J Investig Med High Impact Case Rep; 2020; 8():2324709620933427. PubMed ID: 32536280
[TBL] [Abstract][Full Text] [Related]
10. Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.
Manfredi S; Thiebot T; Henno S; Falize L; Bretagne JF; Meunier B
J Gastrointest Surg; 2009 Dec; 13(12):2309-13. PubMed ID: 19585173
[TBL] [Abstract][Full Text] [Related]
11. Mystery of neck lump: an uncommon presentation of urachal cancer.
Sahu KK; Pandey D; Mishra AK; O'Shea J; Chen Y; McGregor B
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451464
[TBL] [Abstract][Full Text] [Related]
12. A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine.
Prensner JR; Putra J; Vargas SO; Church AJ; Janeway KA; McCleary NJ; DuBois SG
Pediatr Blood Cancer; 2021 Apr; 68(4):e28780. PubMed ID: 33314665
[No Abstract] [Full Text] [Related]
13. Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report.
Chen J; Cheng CS; Chen J; Lv L; Shen X; Zheng L
J Int Med Res; 2020 Nov; 48(11):300060520964355. PubMed ID: 33203264
[TBL] [Abstract][Full Text] [Related]
14. Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer.
Hess LM; Rajan N; Winfree K; Davey P; Ball M; Knox H; Graham C
Adv Ther; 2015 Dec; 32(12):1248-62. PubMed ID: 26650816
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Onal Y; Uzunoglu S; Cicin I
Mol Clin Oncol; 2015 Sep; 3(5):1160-1164. PubMed ID: 26623070
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
18. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
19. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy.
Perego P; Robert J
Cancer Chemother Pharmacol; 2016 Jan; 77(1):5-18. PubMed ID: 26589793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
